Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits. Large vector doses also trigger an immune response as a significant fraction of the vectors fails to traffic efficiently to the nucleus and is targeted for degradation by the host cell proteasome machinery. We have reported that epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) signaling negatively affects transduction by AAV2 vectors by impairing nuclear transport of the vectors. We have also observed that EGFR-PTK can phosphorylate AAV2 capsids at tyrosine residues. Tyrosine-phosphorylated AAV2 vectors enter cells efficiently but fail to transduce effectively, in part because of ubiquitination of AAV capsids followed by proteasome-mediated degradation. We reasoned that mutations of the surface-exposed tyrosine residues might allow the vectors to evade phosphorylation and subsequent ubiquitination and, thus, prevent proteasome-mediated degradation. Here, we document that site-directed mutagenesis of surface-exposed tyrosine residues leads to production of vectors that transduce HeLa cells ≈10-fold more efficiently in vitro and murine hepatocytes nearly 30-fold more efficiently in vivo at a log lower vector dose. Therapeutic levels of human Factor IX (F.IX) are also produced at an ≈10-fold reduced vector dose. The increased transduction efficiency of tyrosine-mutant vectors is due to lack of capsid ubiquitination and improved intracellular trafficking to the nucleus. These studies have led to the development of AAV vectors that are capable of high-efficiency transduction at lower doses, which has important implications in their use in human gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous mutagenesis and biophysical studies have reported the importance of some of these residues in virus assembly, production (Grieger et al., 2006; Wu et al., 2000), infectivity (Zhong et al., 2008), and pH-induced changes during trafficking (Nam et al., 2011; Salganik et al., 2012).”
From Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2 (2020) · cites this paper as Zhong et al., 2008
In the citing paper
“Therefore, mutation of surface tyrosine has been suggested, which resulted in reduced presentation of AAV capsid, decreased T-cell toxicity, and required therapeutic dose [100, 225, 229].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [229]
In the citing paper
“Since surface-exposed residues on AAV capsids can be ubiquitinated through phosphorylation, mutations of these residues (e.g. tyrosine, lysine, serine) to reduce the likelihood of ubiquitination can generate novel capsids with reduced ubiquitination, antigen presentation, and activated cellular immunity (92 -99).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [93]
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648 · cited 1×
“The icosahedral two-, three- and fivefold related VP3 monomers were generated by applying icosahedral symmetry operators to a reference monomer, using the program O (46) on a Silicon graphics Octane workstation.”
MethodManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Self-citationXiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells
Muzyczka, N. (1992) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-75608-5_5 · Cited by 754 · cited 1×
“T adeno-associated virus 2 (AAV2) is a nonpathogenic human parvovirus, which has gained attention as an alternative to the more commonly used retrovirus- and adenovirusbased vectors for gene transfer and gene therapy (1, 2).”
BackgroundSelf-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“It was concluded that this CD8 T cell response to input capsid eliminated AAV2-transduced hepatocytes (43).”
BackgroundαVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Cited by
Items 501–567 of 567
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_150 · Cited by 1
Immunogenicity of AAV Gene Therapy Products
Jawa, V., & Wu, B. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch5 · Cited by 1
Heavy-chain immunoglobulin locus editing in rhesus macaque B cells to confer antibody production
Kuhlmann, A.-S., Madkhali, N., Moskovitz, E., Parrott, J. E., Raman, S. S., Riker, A. O., Martinez-Reyes, J., Gupta, M., Jang, R. A., Nelson, V., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101598 · Cited by 2
“44–48 Anticipating future applications in B cells from SHIV-infected and ART-suppressed RMs, we also evaluated scAAV-2, -5, or -6 transduction using the same protocol as for uninfected B cells (Figure 3A).”
Hellström, M. (2010) · UWA Profiles and Research Repository (University of Western Australia) · Cited by 1
Gong, H., Yuan, N., Shen, Z., Tang, C., Shipp, S. D., Qian, L., Lu, Y., Andolina, I. M., Zhang, S., Wu, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.08.139667 · Cited by 1
“…tropisms, new rAAV variants with superior efficacy have been engineered through capsid transformation (Broekman et al., 2006), amino acid mutation (Zhong et al., 2008), domain/subunit swapping (Rabinowitz et al., 2004), or screened from mutant capsid libraries (Deverman et al., 2016; Maheshri et…”
MethodAskou, A. L., & Corydon, T. J. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2389-2_3
Ramesh, B., Oksana, V., Aamer, M., Assaad, Y., Shelly, M., Christopher, P., David, L., Donald, W., & Scott, A. (2011) · InTech eBooks · doi:10.5772/22677
“(7) By using triple-capsid mutant, pACG2-3M (Y444F, Y500F & Y730F)(7), along with the self-complimentary rAAV vector, we achieved a significant enhancement in rAAV2-sc green fluorescent protein (GFP) mediated transduction (Fig-1).”
BackgroundInfluentialExpanding AAV cargo capacity for gene therapy of Stargardt disease
Trapani, I. (2014)
Maina, C. N. (2009) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1689
Nakai, H. (2009) · Drug Delivery System · doi:10.2745/dds.24.582 · Cited by 1
Gene Therapy and Muscles: The Use of Adeno-associated Virus—Where are We Today?
Wang, B. (2010) · Operative Techniques in Orthopaedics · doi:10.1053/j.oto.2009.10.011
Advances in homology directed genetic engineering of human pluripotent and adult stem cells
Ramamoorthi, K., Curtis, D., & Asuri, P. (2013) · World Journal of Stem Cells · doi:10.4252/wjsc.v5.i4.98
Keeler, A. M. (2012) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/h18g-zn27
“Specific tyrosines in the AAV capsid have been identified which can be phosphorylated causing impaired transduction and trafficking, however making point mutations to these tyrosines allows for high efficiency transduction by avoiding ubiquitination and proteasome-mediated degradation(92).”
BackgroundMolecular mechanisms of acute axonal degeneration in the rat optic nerve
Zhang, J.-N. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5410
Mieda, M., & Sakurai, T. (2015) · Neuromethods · doi:10.1007/978-1-4939-2944-3_7
“For producing AAV-2 vectors used in the studies described previously, we used pACG-2-Y730F (63), which contains a mutant form of AAV2 capsid protein, as the”
BackgroundMethodInfluentialChemical Modulation of AAV Trafficking
Berry, G. E. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dpe3-gy73
Martin, C., Mayer, C., Qiao, C., Yuan, Z., Yang, L., Li, J., Li, J., & Xiao, X. (2015) · Molecular Therapy · doi:10.1016/s1525-0016(16)33926-0
Intracellular fate of AAV particles in human Dendritic Cell and impact on Gene Transfer
Rossi, A. (2016) · theses.fr (ABES) · doi:10.70675/4518d4eazdbd8z4f46z96e2zf87942913c70
“In order to reduce the amount of capsid antigens presented by transduced cells, vectors were designed to increase the transduction efficiency (allowing a reduction of the vectors doses in medical applications), or to escape the UPS [186], [189].”
BackgroundWarischalk, J. K. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dqdt-1s58 · Cited by 1
Improving Aav Transduction Efficiency In Retinal Bipolar Cells For Optogenetic Vision Restoration
Cui, S. (2018) · Human Biology
Xiao, P. (2013) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/rn9x-xq74
Nicolson, S. C. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/gbv4-z740
Gene Therapy for Retinal Disease
McClements, M. E., & MacLaren, R. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00011-7 · Cited by 1
Weber‐Adrian, D. (2017) · TSpace (University of Toronto)
Rescue of inherited retinal degeneration associated with Aipl1 defects
Ku, C. A. (2012) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.4880
マルチトーン信号のピーク対平均電力比(PAPR)を低減する初期位相設定法
楢橋, 祥., & 野島, 俊. (1995) · Cited by 3
Vahsen, B. F. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8894
Remembrances of Nicholas Muzyczka, PhD
(2023) · Human Gene Therapy · doi:10.1089/hum.2023.29240.nmu
Gene Therapy for Ophthalmic Diseases
Igarashi, T. (2023) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.19.242
27. KOŠICKÝ MORFOLOGICKÝ DEŇ: Miesto morfológie v súčasnej medicíne
Košiciach, U. P. J. Š. V., & Hvizdošová, N. (2024) · Univerzita Pavla Jozefa Šafárika, Vydavateľstvo ŠafárikPress eBooks · doi:10.33542/kmd-0313-5
Gene Expression and Editing in Mammalian Retinal Ganglion Cells
Tran, N. M., Xu, X., Qi, L. S., & Hu, Y. (2024) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-99-4436-1_19 · Cited by 1
Wang, H., Kwak, S. E., Renaud, A. F., Hao, J., Kong, L., Fortman, B. A., Pan, X., Duan, D., & Cartee, G. D. (2025) · Advances in Gerontology · doi:10.1134/s2079057025600016
“Serotype AAV9 Y731F tyrosine mutant AAV9 was prepared as described [29, 30].”
Zinser, L. J. (2025) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.94337
Influence of the SUMOylation pathway on adeno-associated virus vector transduction
Chen, Q. (2019) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00026666
Nakahama, R., Saito, A., Nobe, S., Togashi, K., Suzuki, I., Uematsu, A., & Emoto, K. (2022) · Figshare · doi:10.6084/m9.figshare.20454607
Biber, J., Jabri, Y., Glänzer, S., Dort, A., Hoffelner, P., Schmidt, C. Q., Bludau, O., Pauly, D., & Grosche, A. (2024) · Figshare · doi:10.6084/m9.figshare.26684625
Shin, H.-S., Cho, S.-Y., Kwon, Y., Jung, S.-M., Seo, E. S., Son, Y. M., Kim, E. T., Kim, D., & Kim, K.-D. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1716928
“Gene therapy has emerged as a promising approach for treating a wide range of inherited and acquired diseases, with the efficacy and safety of this approach depending on the gene delivery vehicle (Naldini, 2015; Zu and Gao, 2021; Lundstrom, 2023).”
Optimized AAVrh10 and Factor 9 vectors demonstrate improved phenotypic rescue in hemophilia B mice
Huda, S., Senthilkumar, M. B., Bihani, D., Sarangi, P., Kumar, G. N., Chandra, D., & Jayandharan, G. R. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109655
Approches de thérapies géniques pour des maladies neuromusculaires
Moulay, G. (2010) · theses.fr (ABES) · doi:10.70675/e7c5d58ez3cc2z4a72z8d92z6b13cb1ea30c · Cited by 1
Approche multifactorielle de la dégénérescence parkinsonienne
Bourdenx, M. (2015) · theses.fr (ABES) · doi:10.70675/f6aa376dz6eaez4e96zb4cbz719043b97956 · Cited by 1
Emptoz, A. (2016) · theses.fr (ABES) · doi:10.70675/e5c0a59fz4981z4f58z8ba0zc9c6621e7bca · Cited by 1
Characterisation of AAV capsid-specific CD8+ T cell responses in human subjects
Vandamme, C. (2016) · theses.fr (ABES) · doi:10.70675/371e4bbfze69az417bz960azf9db02287546
Chansel‐Debordeaux, L. (2017) · theses.fr (ABES) · doi:10.70675/6b80556ez59a7z4009za535zb2fd974484d2
Thermostability of Adeno-Associated Virus (AAV) Vectors
Pacouret, S. (2018) · theses.fr (ABES) · doi:10.70675/33e13ef9z7aefz418dz8fdez21352cc194bc
Modification chimique d’AAV pour la thérapie génique
Leray, A. (2021) · theses.fr (ABES) · doi:10.70675/c33b1ba2z6c22z40e1z9a98z3ed26b698b7a
Thérapie génique translationnelle des surdités et troubles vestibulaires d'origine génétique
Lahlou, G. (2020) · theses.fr (ABES) · doi:10.70675/d992d926z590ez4d57zbb4fza9922aca932f
Synaptopathies auditives et vestibulaires : de la physiologie moléculaire à la thérapie génique
Calvet, C. (2020) · theses.fr (ABES) · doi:10.70675/8920e327zd8ffz457ez9711zcfc53af428dc
Chassagne, J. (2019) · theses.fr (ABES) · doi:10.70675/74df0299z4167z4397zb93fz28bc889326f4
Gardin, A. (2023) · theses.fr (ABES) · doi:10.70675/ac839ccez52b2z45bez9294ze72731823d9b · Cited by 1
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
CRISPR-Cas9-based strategies for enhanced targeted integration
Lacombe, L. (2024) · theses.fr (ABES) · doi:10.70675/9c9d279dz512az4b72z8322zea205cef9b67 · Cited by 1
Masaki, T., Watanabe, M., Mandai, M., Kihara, M., Abe, T., & Kageyama, R. (2026) · Cell Reports · doi:10.64898/2026.04.18.719349
Kumar, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-7688-3_3
Status and future of recombinant adeno‐associated virus vector manufacturing
Agbogbo, F., & Dismuke, D. J. (2026) · Biotechnology Progress · doi:10.1002/btpr.88525
“101 In another study, a domain-swapping strategy was employed to generate 27 chimeric capsid genes, which contained exchanged domains between AAV2 and AAV8.”
Uchida, Y., Mori, Y., Kurinomaru, T., Aoki, R., Uchiyama, S., Hirai, H., & Muraguchi, T. (2026) · Scientific Reports · doi:10.1038/s41598-026-56897-5
Lavado‐García, J., Bosch-Molist, L., Ruiz-Ayala, C., Jorge, I., Vázquez, J., Gòdia, F., & Cervera, L. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201815
“Capsid engineering strategies, including rational design and directed evolution have further expanded their therapeutic potential by improving tissue targeting and enabling access to additional organs, 2–4 resulting in broad serotype-dependent tissue tropisms.”
Pooley, J. R., Bienemann, A. S., Young, A., Hollings, O., Wu, J., Mayo, E., Chu, C. J., & Singleton, W. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00831-4 · Cited by 1
“Y445F, introduced separately, enhances transduction by avoiding ubiquitination and proteasomal degradation, and may resist neutralising antibodies [48, 68, 69].”
Huang, Z., Zhang, L., Ma, H., Wang, Z., Li, H., Hu, X., Zhou, M., He, M., Wu, J., Cheng, L., et al. (2026) · Autophagy · doi:10.1080/15548627.2026.2759842
Sullivan, T. (2011) · doi:10.21007/etd.cghs.2011.0389
“Mutating these surface-exposed tyrosines lead to the creation of rAAV vectors that express over 8 fold higher in muscle tissue than controls [280-281].”
BackgroundPotentiel thérapeutique de la dystrophine-dp71 et barrières rétiniennes
Vacca, O. (2014) · theses.fr (ABES) · doi:10.70675/ec7a47b3z5fc2z4fe5z9076zd4d307e6f9be · Cited by 1
(1999) · doi:10.1002/1529-0131(199901)42:1<76::aid-anr10>3.0.co;2-g
Metadata
- Authors
- Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., Muzyczka, N., & Srivastava, A.
- Affiliations
- *Division of Cellular and Molecular Therapy, Department of Pediatrics,
- Powell Gene Therapy Center and Genetics Institute,
- University of Florida Health (US)
- UF Health Cancer Center (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-06-03
- Volume
- 105
- Issue
- 22
- Pages
- 7827-7832
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2402387
- OpenAlex
- W2122236774
- Cited by
- 558
- References
- 53
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 30 · 2023: 31 · 2022: 29 · 2021: 43 · 2020: 38 · 2019: 31 · 2018: 27 · 2017: 34 · 2016: 29 · 2015: 38 · 2014: 34 · 2013: 44 · 2012: 24
- FWCI
- 18.28
- Type
- journal article
- Language
- en
- Update notices
- correction (2008-08-05)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- National Institutes of Health (Project 3)
- National Heart, Lung, and Blood Institute (P01-HL51811, P01HL059412, P01HL051811, R01 HL-07691, R01HL065570, R01HL-65570, P01HL078810)
- National Institute of General Medical Sciences (R01GM082946)
- National Institute of Allergy and Infectious Diseases (R01AI051390)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, R01DK062302)
- National Institute of Biomedical Imaging and Bioengineering (R01EB002073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- tyrosine mutations, proteasomal degradation, nuclear transport, transduction efficiency, factor IX, gene therapy vectors, hepatocytes
- MeSH terms
- Dependovirus, Animals, Capsid, Cell Nucleus, Genetic Vectors, HeLa Cells, Humans, Mice, Inbred C57BL, Phosphorylation, Transduction, Genetic, Tyrosine, Genetic Therapy, Point Mutation, Hepatocytes, Mice, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.